Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING LLC

Lab Prepares Launch of Trisomy 21 Diagnostic Test

By Labmedica International staff writers
Posted on 23 Aug 2010
A new 650-m2 laboratory will launch the Trisomy 21 (T21) diagnostic test; the launch is planned for the latter half of the year 2011.

The lab will perform validation for Sequenom's (San Diego, CA, USA) T21 noninvasive Down syndrome test. Ian Clements, senior director of the company's investor relations said that samples are currently being collected for a clinical study. About 4,000 samples will be run at the new facility in connection with the final validation of the T21 test.

The clinical trial is being led by scientists at the Women and Infants Hospital (Providence, RI, USA), which is affiliated with Brown University (Providence, RI, USA). The test is sensitive enough to identify fetal DNA circulating in the pregnant woman's blood.

Sequenom has a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited lab, the Sequenom Center for Molecular Medicine, which runs the company's cystic fibrosis and SensiGene fetal Rhesus D genotyping tests. A test for age-related macular degeneration, to be launched in the first half of 2011, will also be run out of the Grand Rapids facility. Those tests are run on Sequenom's MassArray technology, whereas the T21 test will run on sequencing technology.

"This is basically an expansion of our lab network," remarked Mr. Clements. "The core of our sequencing expertise and knowledge is here in San Diego, hence it made sense to expand our network and build a CLIA lab here."

Sequenom has a CLIA-certified and CAP-accredited lab, the Sequenom Center for Molecular Medicine, which runs the company's cystic fibrosis and SensiGene fetal Rhesus D genotyping tests. A test for age-related macular degeneration, to be launched in the first half of 2011, will also be run out of the Grand Rapids facility.

These tests are run on Sequenom's MassArray technology, whereas the T21 test will run on sequencing technology.

Sequenom anticipates getting CLIA certification and CAP accreditation for the San Diego lab in Q4 2010, he added.

Related Links:

Sequenom
Women and Infants Hospital
Brown University



KARL HECHT GMBH & CO KG
CELLAVISION AB
MEDLAB Asia
PERIPHERAL VISIONS INC

Channels

Genetic Tests

view channel
Image: Histopathology of tuberculoid leprosy in a skin section (Photo courtesy Dr. D.S. Ridley, Wellcome Images).

Genes Discovered Influence Risk of Developing Leprosy

Leprosy, a chronic dermatological and neurological disease, is caused by infection with Mycobacterium leprae, and its manifestation, progression and prognosis are strongly associated with the proficiency... Read more

Hematology

view channel
Image: Plastic bag containing 0.5 to 0.7 liters of packed red blood cells in citrate, phosphate, dextrose, and adenine (CPDA) solution (Photo courtesy of Fresenius HemoCare).

Transfusion Protocols Compared After Cardiac Surgery

Unnecessary blood transfusions may increase healthcare costs both directly, because blood is an increasingly scarce and expensive resource, and indirectly due to the complications associated with transfusion.... Read more

Industry News

view channel

Latin America’s IVD Sector Exceeds USD 2 Billion, Brazil leads

The Latin American in vitro diagnostics (IVD) sector was estimated at USD 2.4 billion in 2014. Population growth, government insurance, newly insured patients, and updated healthcare facilities have driven growth in the region and will continue to propel demand, according to Kalorama Information (New York, NY, USA).... Read more
 

Events

06 Apr 2015 - 08 Apr 2015
07 Apr 2015 - 09 Apr 2015
13 Apr 2015 - 16 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.